Publication:
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

Identifiers

URI: http://hdl.handle.net/20.500.12105/20381

ISSN: 0887-6924

DOI: 10.1038/leu.2017.58

Full text access: http://hdl.handle.net/20.500.13003/10944

SCOPUS: 2-s2.0-85014659967

WOS: 402832700025

Publication date

Authors

Martinez-Lopez, J

Sanchez-Vega, B

Ruiz-Heredia, Y

Publishers

Nature Publishing Group

Metrics

Export

MeSH Terms

Aged Male Monitoring, Physiologic Multiple Myeloma Neoplasm, Residual Female High-Throughput Nucleotide Sequencing Humans Survival Analysis Antineoplastic Combined Chemotherapy Protocols

DeCS Terms

Humanos Protocolos de Quimioterapia Combinada Antineoplásica Análisis de Supervivencia Anciano Monitoreo Fisiológico Mieloma Múltiple Femenino Secuenciación de Nucleótidos de Alto Rendimiento Neoplasia Residual Masculino

Bibliographic citation

Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma [letter]. Leukemia. 2017 Jun;31(6):1446-9. Epub 2017 Feb 17.

Collections

IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)
IdiSNA - Instituto de Investigación Sanitaria de Navarra (Navarra)

Publisher version

https://dx.doi.org/10.1038/leu.2017.58

Document type

letter to the editor